Neoadjuvant tislelizumab with chemoradiotherapy for resectable locally advanced esophageal squamous cell carcinoma
{{output}}
Background: Combining neoadjuvant immunotherapy with chemoradiotherapy may improve outcomes in esophageal cancer; however, factors underlying its effectiveness remain unclear. This study evaluated the efficacy of neoadjuvant tisl... ...
